ENSG
The short version: Ensign kept the machine running
Ensign Group didn’t exactly show up to its Q1 2026 call with a sad trombone. The company said revenue rose 18.4% in the quarter and it lifted full-year earnings guidance to $7.48-$7.62 per diluted share. In other words: the business is still doing what investors like best — growing, then telling you it might grow a little more.
Why the stock crowd should care
The big takeaway here is that Ensign’s growth isn’t coming from a one-off sugar rush. Management pointed to record occupancy, strong demand in skilled nursing, and continued patient trust in local operations. Even with some concern around managed care volumes, the company sounded pretty comfortable that the underlying demand picture is holding up.
Acquisitions, but make it a lifestyle
Ensign also said it has acquired 22 new operations, mostly in Texas. That’s a nice reminder that part of this story is still old-school roll-up math: buy good assets, improve operations, repeat. If the company can keep layering on deals while maintaining clinical quality, the growth story gets a lot more interesting.
A few extra nuggets that matter:
- 85% of operations now have a four- or five-star quality rating
- turnover remains low, which matters when healthcare labor can feel like musical chairs
- management continues to lean on its decentralized model and local leadership, the corporate version of “don’t micromanage the people actually doing the work”
Big picture
For investors, this was basically Ensign saying: the business is growing, the guidance is going up, and the operating model is still working. Not bad for a day’s work.